Alert detail
LCD L38584: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — CGS
What changed
New MolDX policy may alter tumor cell testing reimbursement.
Who’s affected: Oncology billing teams · Effective: April 16, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 4 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.